Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 23.4% is a hypertonic saline solution that increases serum osmolality, drawing water from intracellular space into extracellular space, thereby expanding intravascular volume and reducing cerebral edema. It also acts as an electrolyte replenisher.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of symptomatic hyponatremia,Reduction of intracranial pressure in patients with cerebral edema or increased intracranial pressure,Management of severe hypovolemia when rapid volume expansion is needed
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
IV: 50-100 m L of 23.4% sodium chloride (11.7-23.4 g Na Cl) infused over 1-2 hours for hyponatremia; rate not to exceed 0.5 m Eq/L/h correction.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable as a terminal elimination half-life; sodium and chloride are electrolytes regulated by homeostatic mechanisms; plasma concentrations normalize within minutes to hours depending on volume status and renal function.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Sodium and chloride are not metabolized; they are excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal; >95% of administered sodium and chloride ions excreted unchanged in urine via glomerular filtration and tubular reabsorption/regulation; negligible biliary/fecal elimination.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Minimal to none; sodium and chloride are not significantly bound to plasma proteins (<0.1% bound).
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 0.15-0.3 L/kg; corresponds to extracellular fluid volume; sodium distributes primarily in extracellular space with minimal intracellular penetration.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%; no oral or other relevant routes for the 23.4% hypertonic solution; oral bioavailability not applicable due to enteral use of different formulations.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR >60: no adjustment; GFR 30-59: caution, monitor sodium; GFR 15-29: avoid if possible; GFR <15: contraindicated.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh A/B: standard dosing with caution; Child-Pugh C: avoid due to risk of fluid overload and encephalopathy.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
For hyponatremia: 0.5-1 m L/kg 23.4% Na Cl (2-4 m Eq/kg) IV over 1-2 hours; max 100 m L/dose. Correction rate max 0.5 m Eq/L/h.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Initiate at lower end of adult dose; monitor volume status and serum sodium closely due to reduced renal function and higher risk of fluid overload.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Rapid correction of chronic hyponatremia (>0.5 m Eq/L/h) may cause osmotic demyelination syndrome (central pontine myelinolysis). Infusion rate must be carefully monitored.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of fluid overload, especially in patients with heart failure, renal impairment, or cirrhosis,Risk of hypernatremia and hyperchloremic metabolic acidosis with excessive administration,Extravasation may cause tissue necrosis,Use with caution in patients with impaired renal function, electrolyte abnormalities, or conditions predisposing to fluid overload
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypernatremia,Hypersensitivity to sodium chloride,Fluid retention states such as congestive heart failure, pulmonary edema, or peripheral edema,Severe renal impairment with oliguria or anuria
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. Maintain a consistent dietary sodium intake as advised by your healthcare provider; avoid excessive water intake during treatment.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
SODIUM CHLORIDE 23.4% is a hypertonic saline solution used for correction of severe hyponatremia or as an osmotic agent. Teratogenicity is not expected from sodium chloride itself; however, rapid correction of hyponatremia may cause maternal osmotic demyelination, which could secondarily affect fetal well-being. No direct fetal risks are documented in the first trimester. In second and third trimesters, excessive sodium administration may cause maternal hypernatremia and volume expansion, potentially leading to placental edema or fetal hypernatremia. Use cautiously and avoid extreme electrolyte shifts.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Sodium chloride is a normal constituent of breast milk. Hypertonic saline administration may transiently increase milk sodium content. The milk-to-plasma (M/P) ratio for sodium is approximately 1.0 due to passive diffusion. Clinically significant effects on the breastfed infant are unlikely with appropriate dosing. However, high maternal doses causing hypernatremia could theoretically lead to hypernatremia in the infant. Monitor infant for signs of salt overload.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy does not require dose adjustments for sodium chloride per se. However, physiologic plasma volume expansion in pregnancy may dilute serum sodium, potentially increasing the risk of overcorrection of hyponatremia. Use lower infusion rates and more frequent monitoring of serum sodium. Maximum rate of correction should not exceed 10-12 m Eq/L in 24 hours to avoid osmotic demyelination. No pharmacokinetic changes specific to pregnancy necessitate dose changes.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
23.4% sodium chloride is a hypertonic solution used primarily for severe hyponatremia (serum Na+ <120 m Eq/L with neurological symptoms). Administer via central line only due to high osmolarity (8000 m Osm/L). Infuse at 1-2 m L/min with frequent serum Na+ monitoring; target correction rate ≤8 m Eq/L in 24 hours to prevent osmotic demyelination syndrome. Do not use in patients with heart failure, renal impairment, or hypervolemia.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is used to correct severely low sodium levels in the blood.,It must be given through a large vein (central line) to prevent damage to small veins.,Your sodium levels and neurological status will be monitored closely during infusion.,Report any symptoms like headache, nausea, confusion, or muscle twitching immediately.,Do not adjust the infusion rate yourself; it is controlled by medical staff.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 23.4% is a hypertonic saline solution that increases serum osmolality, drawing water from intracellular space into extracellular space, thereby expanding intravascular volume and reducing cerebral edema. It also acts as an electrolyte replenisher.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is: IV: 50-100 m L of 23.4% sodium chloride (11.7-23.4 g Na Cl) infused over 1-2 hours for hyponatremia; rate not to exceed 0.5 m Eq/L/h correction.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is classified as Category A/B. SODIUM CHLORIDE 23.4% is a hypertonic saline solution used for correction of severe hyponatremia or as an osmotic agent. Teratogenicity is not expected from sodium chloride itself;. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.